Park Avenue Securities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Park Avenue Securities’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$475K	Buy	+3,003	New	+$406K	﹤0.01%	1316
2025 Q2	–	Sell	-3,309	Closed	-$268K	–	1582
2025 Q1	$268K	Buy	+3,309	New	+$296K	﹤0.01%	1037
2024 Q4	–	Sell	-46,989	Closed	-$4.64M	–	1524
2024 Q3	$4.64M	Buy	46,989 +43,417	+1,215%	+$4.27M	0.05%	239
2024 Q2	$331K	Buy	+3,572	New	+$320K	﹤0.01%	1150
2023 Q1	–	Sell	-3,521	Closed	-$292K	–	1177
2022 Q4	$292K	Buy	3,521 +305	+9%	+$24.7K	0.01%	994
2022 Q3	$255K	Buy	3,216 +492	+18%	+$41.5K	0.01%	976
2022 Q2	$202K	Buy	+2,724	New	+$204K	﹤0.01%	1062

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Park Avenue Securities's XBI Position: Q2 2026 in Review

Park Avenue Securities opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 3,003 shares worth $475K. The stake represents ﹤0.01% of the portfolio and ranks #1316 among its holdings. This is a return to the name: Park Avenue Securities previously reported a position in XBI as recently as Q1 2025.

Park Avenue Securities first reported a position in XBI in Q2 2022 and has held it in 7 quarters since. The position peaked at $4.64M in Q3 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Park Avenue Securities held 3,003 shares of State Street SPDR S&P Biotech ETF worth $475K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Park Avenue Securities position in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1316 holding.
Park Avenue Securities first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 7 quarters since.
Park Avenue Securities's State Street SPDR S&P Biotech ETF position peaked at $4.64M in Q3 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.